REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$930.67
−4.39%Next report
Analyst consensus
- Next report date
- Jan 28, 2027
- EPS estimate
- $25
- Revenue estimate
- $5.9B
Latest reported
- Last report date
- Oct 30, 2026
- EPS actual
- $20
- EPS estimate
- $17
- Revenue actual
- $5.1B
- Revenue estimate
- $4.6B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +18.8%
- Revenue beats (12Q)
- 11
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $956
- PT range
- $812 – $1.2K
- Analysts
- 20
13 Buy7 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 30, 2026 | $17 | $20 | Beat 21.56% | $5.1B |
| Jul 30, 2026 | $10 | $14 | Beat 40.65% | $4.3B |
| Apr 29, 2026 | $8.91 | $9.47 | Beat 6.29% | $3.6B |
| Jan 30, 2026 | $11 | $11 | Beat 6.52% | $3.9B |
| Aug 1, 2025 | $8.43 | $13 | Beat 52.91% | $3.7B |
| Feb 4, 2025 | $11 | $12 | Beat 7.50% | $3.8B |
| Oct 31, 2024 | $12 | $12 | Beat 6.58% | $3.7B |
| Aug 1, 2024 | $11 | $12 | Beat 9.05% | $3.5B |
| May 2, 2024 | $10 | $9.55 | Miss -6.14% | $3.1B |
| Feb 2, 2024 | $11 | $12 | Beat 10.49% | $3.4B |
| Nov 2, 2023 | $11 | $12 | Beat 8.46% | $3.4B |
| Aug 3, 2023 | $9.76 | $10 | Beat 4.88% | $3.2B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Jan 28, 2027